IN8BIO, Inc. is a biotechnology company that was founded in 2018. The company is dedicated to developing innovative therapies for the treatment of solid tumor cancers. IN8BIO's mission is to improve the lives of patients by addressing the unmet medical needs in the field of oncology.
IN8BIO focuses on the development of targeted therapies that harness the body's immune system to fight cancer. The company utilizes a proprietary technology platform called Gamma Delta T Cell Engager (GADLEN™) to engineer novel therapies that engage and activate gamma delta T cells, a specialized type of immune cell with potent anti-cancer activity.
Through its research and development efforts, IN8BIO aims to advance its pipeline of therapeutic candidates and bring novel treatment options to patients with solid tumor cancers. The company is dedicated to conducting rigorous clinical trials to evaluate the safety and efficacy of its therapies and to gain regulatory approvals for their use.
In terms of its public status, as of my knowledge cutoff in September 2021, IN8BIO had not yet gone public. It is important to note that the status of a company going public may have changed since then. Going public can provide additional financial resources to support the company's research and development activities and further advance its mission of developing effective cancer therapies.
IN8BIO's focus on addressing solid tumor cancers and its commitment to leveraging the immune system's potential for fighting cancer highlight its dedication to improving patient outcomes. By combining scientific innovation, advanced technology platforms, and clinical expertise, IN8BIO strives to make a significant impact in the field of oncology and contribute to the advancement of cancer treatment options.